[An association between the FABP2 gene polymorphism and efficacy of valproates].
To search for association between the 163G>A polymorphism of the fatty acid binding protein 2 (FABP2) gene and intracellular transport of the valproic acid in the small intestines, 168 patients with different forms of epilepsy, aged from 1 to 89 years, and different illness duration have been studied. The patients received valproates (127 patients) and topiramate (41 patients) as a monotherapy. It has been shown that the 163G>A (Ala54Thr) polymorphism exerts an influence on effective dose of the valproic acid but not of topiramate.
Aksenova
M G
MG
Burd
S G
SG
Kachalin
E Iu
EIu
Avakian
G N
GN
Badalian
O L
OL
Savenkov
A A
AA
Tertyshnik
O Iu
OIu
Dorofeeva
M Iu
MIu
Belousova
E D
ED
Gusev
E I
EI
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001693:Biological Transport, Active / Q000502:physiology; D002648:Child; D002675:Child, Preschool; D004247:DNA / Q000235:genetics*; D004827:Epilepsy / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D050556:Fatty Acid-Binding Proteins / Q000235:genetics*; D005632:Fructose / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D005787:Gene Frequency; D006801:Humans; D007223:Infant; D007421:Intestine, Small / Q000378:metabolism; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D000077236:Topiramate; D016896:Treatment Outcome; D014635:Valproic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000927:Anticonvulsants; C493404:FABP2 protein, human; D050556:Fatty Acid-Binding Proteins; D000077236:Topiramate; D005632:Fructose; D014635:Valproic Acid; D004247:DNA